Contrast Induced Nephropathy

¹⁾ Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT--a pooled analysis of two randomized trials.

Thomsen HS, Morcos SK. Eur Radiol. 2009 Apr;19(4):891-7. Epub 2008 Nov 11.

View

²⁾ ESUR guidelines on contrast media.

Thomsen HS, Morcos SK; ESUR. Abdom Imaging. 2006 Mar-Apr;31(2):131-40.

View

³⁾ The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography.

Thomsen HS, Morcos SK, Erley CM, Grazioli L, Bonomo L, Ni Z, Romano L; Investigators in the Abdominal Computed Tomography: IOMERON 400 Versus VISIPAQUE 320 Enhancement (ACTIVE) Study.Invest Radiol. 2008 Mar;43(3):170-8.

View

⁴⁾ Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention.

Wessely R, Koppara T, Bradaric C, Vorpahl M, Braun S, Schulz S, Mehilli J, Schömig A, Kastrati A; Contrast Media and Nephrotoxicity Following Coronary Revascularization by Angioplasty Trial Investigators. Circ Cardiovasc Interv. 2009 Oct;2(5):430-7. Epub 2009 Sep 22.

View

Contact us

Please fill out the form below and we will get back to you.

Different countries may have specific processes in place to handle reports of adverse reactions. To report an adverse reaction related to Bracco products, you can find specific contacts and information selecting the page "Pharmacovigilance" of your country.

I have read and I agree with the Bracco Privacy Policy

* I have read the BraccoHealthCare Professionals Privacy Notice and I consent to the processing of my personal data allowing Bracco Imaging SpA (Data Controller) to conduct its business or scientific operations and contact me with promotional communication through email, SMS, and other digital and offline channels, such as mobile apps and social media.